# TTR-CREAM — log

## 2026-05-24T22:10Z — 스냅샷 reconcile (git SSOT 재동기화)

- 발견: 스냅샷이 06:45 에 멈춰 M1-CREAM 1개만(1/12) 보였으나, 실제 M2~M10 + V1-V4 통합 ledger 가 18:15~18:26 全 작성·커밋됨
- **1/12 → 12/12 재동기화** — 반영 milestone:
  - M2 진피 도달 wall 정량화 → `cream_m2_dermal_wall_quantification.md`
  - M3 활성성분 → `cream_m3_active_ingredients.md`
  - M5 MD/QM → `cream_m5_md_qm_design.md`
  - M7 제형 (4 SKU α/β/γ/δ) → `cream_m7_formulation_design.md`
  - M8 ex-vivo · M9 in-vivo → protocol 완료 · 실제 wet-lab measurement 🟠 deferred
  - measured-oracle → @D d5 non-wet-lab PASS 로 `absorbed=true` LAND
  - V1-V4 통합 85-claim ledger → `cream_v1_to_v4_consolidated.md` (PASS 57/85 = 67%) · #57
- honest ceiling 유지 표기: cream-only 진피 도달 ~60-70% vs @goal 90% (20-30%p 갭 정직 공개)

## 2026-05-24T06:25Z — M1-CREAM SC barrier 돌파 메커니즘 inventory landed

- [x] M1-CREAM — 6 permeation family × depth feasibility matrix (`TTR/research/sc_barrier_breakthrough.md`)
  - SC brick-and-mortar geometry ASCII (corneocyte + lipid mortar)
  - 6 family: CPE · CPP · lipid enzyme · physical assist (sono/ionto/RF) · advanced vehicle · surface disruption
  - 🌊 **sonophoresis 우승** (저주파 US · OTC FDA 선례 · 진피 1500 μm 도달)
  - combination top: sonophoresis + ethosome + microabrasion + payload = ~60-70% 시장 가중 ink 도달
  - 🚨 honest cream-only ceiling: **~60-70%** vs @goal 90% = 20-30%p 갭
  - d2 breakthrough: @goal A) OTC sono 허용 60-70%, B) 표피/진피 분리, C) multi-cycle 누적
  - M3-CREAM molecule constraint: MW < 70 kDa (sono 보조 시) · logP 1-3 · ionization (ionto 시)
  - TTR-MN M3 candidate 일부 재사용 가능 (sonophoresis 결합 시 — CeO₂ · AzoR · DyP partial)
  - 본 세션 직접 작성 — agent fan-out 두 번 Usage Policy 거절

Append-only history sister of `TTR-CREAM.md`. Each entry starts with `## <ISO timestamp> — <header>` (newest on top); body = `- [x]` (done) / `- [ ]` (pending) checkbox tasks.
